Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin
Konstantin Senkevich, Uladzislau Rudakou, Ziv Gan‐Or
Neuropharmacology (2021) Vol. 202, pp. 108822-108822
Closed Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Monogenic Parkinson’s Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing
Fangzhi Jia, Avi Fellner, Kishore R. Kumar
Genes (2022) Vol. 13, Iss. 3, pp. 471-471
Open Access | Times Cited: 91
Parkinson’s Disease is Predominantly a Genetic Disease
Shen‐Yang Lim, Christine Klein
Journal of Parkinson s Disease (2024) Vol. 14, Iss. 3, pp. 467-482
Open Access | Times Cited: 24
LRRK2 and Parkinson's disease: from genetics to targeted therapy
Yuri L. Sosero, Ziv Gan‐Or
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 6, pp. 850-864
Open Access | Times Cited: 31
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Xuxiang Zhang, Heng Wu, Beisha Tang, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic
Shen‐Yang Lim, Ai Huey Tan, Azlina Ahmad, et al.
The Lancet Neurology (2024)
Closed Access | Times Cited: 9
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases
Nidhi Puranik, Minseok Song
Neurology International (2025) Vol. 17, Iss. 2, pp. 26-26
Open Access | Times Cited: 1
Clinical and functional evidence for the pathogenicity of the LRRK2 p.Arg1067Gln variant
Shen‐Yang Lim, Tzi Shin Toh, Jia Wei Hor, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson’s Disease: a New Genetic State of the Art
Júlio César Claudino dos Santos, Gabriela Braga Cabrera Mano, André Rodrigues da Cunha Barreto Vianna, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 9, pp. 6754-6770
Closed Access | Times Cited: 7
Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease
Jingru Ren, Lei Yan, Hao Zhou, et al.
Neurobiology of Disease (2023) Vol. 185, pp. 106254-106254
Open Access | Times Cited: 15
GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
Young Eun Huh, Tatiana Usnich, Clemens R. Scherzer, et al.
Journal of Movement Disorders (2023) Vol. 16, Iss. 3, pp. 261-278
Open Access | Times Cited: 13
Genetic mutations in Parkinson’s disease: screening of a selected population from North-Eastern Italy
Giulia Bonato, Angelo Antonini, Francesca Pistonesi, et al.
Neurological Sciences (2024)
Open Access | Times Cited: 5
Clinical genetic testing in Parkinson’s disease should become part of routine patient care
Ziv Gan‐Or
Brain (2024) Vol. 147, Iss. 8, pp. 2595-2597
Closed Access | Times Cited: 5
Neurological symptoms in adults with Gaucher disease: a systematic review
Gabriele Imbalzano, Claudia Ledda, Alberto Romagnolo, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 3897-3907
Open Access | Times Cited: 4
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
Malco Rossi, Susen Schaake, Tatiana Usnich, et al.
Movement Disorders (2025)
Open Access
La maladie de Parkinson : de la génétique aux thérapies ciblées
Guillaume Cogan, Alexis Brice
Comptes Rendus Biologies (2025) Vol. 348, Iss. G1, pp. 21-33
Open Access
GDNF reduces fibril-induced early-stage alpha-synuclein pathology after delivery of 20S proteasome inhibitor lactacystin
Şafak Er, Ilmari Parkkinen, Karolina Trepczyk, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107048-107048
Open Access
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease
Konstantin Senkevich, Cornelia E. Zorca, Aliza Dworkind, et al.
Brain (2022) Vol. 146, Iss. 5, pp. 1859-1872
Open Access | Times Cited: 17
International Genetic Testing and Counseling Practices for Parkinson's Disease
Rachel Saunders‐Pullman, Deborah Raymond, Roberto A. Ortega, et al.
Movement Disorders (2023) Vol. 38, Iss. 8, pp. 1527-1535
Closed Access | Times Cited: 10
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review
Eva Schaeffer, Rezzak Yılmaz, Erik K. St. Louis, et al.
Journal of Parkinson s Disease (2024) Vol. 14, Iss. s2, pp. S307-S319
Open Access | Times Cited: 3
Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway
Federica Albanese, Chiara Domenicale, Mattia Volta, et al.
Biochemical Society Transactions (2022) Vol. 50, Iss. 1, pp. 621-632
Closed Access | Times Cited: 15
How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson’s disease?
Abhishek Lenka, Joseph Jankovic
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 2, pp. 107-122
Closed Access | Times Cited: 8
Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson’s Disease
Alena E. Kopytova, Georgy N. Rychkov, Alexander A. Cheblokov, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 9105-9105
Open Access | Times Cited: 7
LRRK2 and Proteostasis in Parkinson’s Disease
María Dolores Pérez‐Carrión, Inmaculada Posadas, Javier Solera, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6808-6808
Open Access | Times Cited: 12
Genome Sequencing in the Parkinson Disease Clinic
Emily J. Hill, Laurie Robak, Rami Al‐Ouran, et al.
Neurology Genetics (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 12
Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
Federico Rodríguez‐Porcel, Kathryn A. Wyman‐Chick, Carla Abdelnour Ruiz, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top